Skip to Content

Vimizim FDA Approval History

FDA Approved: Yes (First approved February 14, 2014)
Brand name: Vimizim
Generic name: elosufase alfa
Dosage form: Injection
Company: BioMarin Pharmaceutical Inc.
Treatment for: Mucopolysaccharidosis Type IVA

Vimizim (elosufase alfa) is an enzyme replacement therapy for patients with Mucopolysaccharidosis Type IVA (Morquio A syndrome).

Development Timeline for Vimizim

DateArticle
Feb 16, 2014Approval FDA Approves Vimizim to Treat Mucopolysaccharidosis Type IVA
Nov 20, 2013FDA Advisory Committee Recommends Approval of Vimizim for Morquio A Syndrome

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.